Results 131 to 140 of about 54,917 (299)

Iron deficiency in heart failure: Epidemiology, diagnostic criteria and treatment modalities

ESC Heart Failure, Volume 12, Issue 2, Page 723-726, April 2025.
Stephan von Haehling
wiley   +1 more source

From cytokine storm to renal scarring in diabetic kidney disease: Biomarkers, risk stratification, and precision therapeutics

Precision Medical Sciences, EarlyView.
Hyperglycemia‐driven cytokine activation initiates a sustained inflammatory cascade in diabetic kidney disease, promoting cellular injury and fibrogenic signaling. Integrating cytokine‐based biomarkers with risk stratification enables precision therapeutics that target inflammation and fibrosis, ultimately aiming to halt progression from early renal ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source

From prediction to intervention: Causal artificial intelligence as the missing link in precision therapeutics

Precision Medical Sciences, EarlyView.
Predictive multiomics artificial intelligence (AI) identifies risk but does not indicate which intervention will change a patient's outcome; causal AI, anchored in biological mechanism, bridges this gap to enable individualized treatment decisions.
Gedion Mengistu Dejen
wiley   +1 more source

Integrative Approaches in Cardiovascular Disease: The Role of Nutraceuticals in Heart Failure, Atrial Fibrillation, and Related Conditions

Phytotherapy Research, EarlyView.
Schematic representation of the shared pathophysiological mechanisms underlying heart failure (HF) and atrial fibrillation (AF), including inflammation, oxidative stress, endothelial dysfunction, and fibrosis. The figure highlights the clinical and mechanistic convergence of conventional pharmacological therapies and selected nutraceuticals in ...
Laura Beatrice Mattioli, Ivan Corazza, Roberta Budriesi, Luca Camarda, Maria Carelli, Alberto Spadotto, Igor Diemberger   +6 more
wiley   +1 more source

Astragaloside IV Restores Autophagy and Inhibits Apoptosis for Podocyte Protection in Diabetic Nephropathy by Inhibiting Notch1 Signaling via SIRT6‐Mediated Deacetylation

Phytotherapy Research, EarlyView.
AS‐IV binds to SIRT6 and promotes H3K9 deacetylation at the Notch1 promoter, inhibiting gene transcription (Created with BioGDP.com). ABSTRACT Astragaloside IV (AS‐IV) has demonstrated efficacy in ameliorating proteinuria and attenuating renal tubular damage in preclinical diabetic nephropathy (DN) models.
Qiyu Yue, Chen Yong, Xinran Wang, Yang Shu, Min Yao, Yongfei Yu, Yubai Xue, Rong Deng, Tianlu Chu, Weiwei Tao, Min Zhao, Enchao Zhou   +11 more
wiley   +1 more source

SGLT2 inhibitors: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 inhibitors (HR, 0.83; 95%CI, 0.77-0.91)

Researka accepted publication: 3591803f-c88e-47e8-a088-a212f55ad36d Source submission: e9ee22f6-f8be-49ba-b6ab-40a834ec19cb The cited direct receipts support a bounded working claim: reduced risk of stroke with SGLT2 inhibitors compared to non-SGLT2 ...
Dominic Lynch
core  

Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease

ESC Heart Failure, Volume 12, Issue 2, Page 1490-1491, April 2025.
Özant Helvacı, Ömer Faruk Akçay, Emre Yaşar, Ülver Derici, Galip Güz   +4 more
wiley   +1 more source

Cardiomyocyte Membrane‐Camouflaged Spinach Nano‐Thylakoids Enhance Myocardial Energy Metabolism and Ameliorate Heart Failure

Small, EarlyView.
Schematic illustration of the construction of MM‐NTU, its cardiac‐targeting behavior, and its light‐activated therapeutic mechanism. Thylakoids isolated from spinach chloroplasts were processed into nano‐thylakoid units (NTU) and further camouflaged with cardiomyocyte membranes to generate MM‐NTU.
Haohui Fan, Bei Song, Chengyun Liu, Peiyu Zhong, Quan Zhou, Xiaofang Zhao, Guangyu Gao, Xinyue Zhang, Xueke Guang, Tianci Yao, Ting Liu, Hao Zhang, Xinqi Diao, Weilin Lu   +13 more
wiley   +1 more source

Blood Pressure‐Lowering Effect of SGLT2 Inhibitors in Patients Without Antihypertensive Treatment: A Real‐World Data Analysis

The Journal of Clinical Hypertension
Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have demonstrated blood pressure (BP)‐lowering effects; however, most studies included patients taking antihypertensive medications.
Reina Ito, Michihiro Satoh, Hideaki Hashimoto, Hiroki Nobayashi, Seiya Izumi, Maya Toyama, Yutaro Iwabe, Yuya Suzuki, Takuo Hirose, Shingo Nakayama, Takahisa Murakami, Masato Sasaki, Hirohito Metoki   +12 more
doaj   +1 more source